A-methapred and Kaletra

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Ritonavir may significantly increase the blood levels of methylPREDNISolone. You may be more likely to experience side effects such as swelling, weight gain, high blood pressure, high blood glucose, muscle weakness, depression, acne, thinning skin, stretch marks, easy bruising, bone density loss, cataracts, menstrual irregularities, excessive growth of facial or body hair, and abnormal distribution of body fat, especially in the face, neck, back, and waist. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Other side effects that may occur include decreased ability to fight infections, increased risk of developing infections, and inadequate response to stress such as infection, surgery, trauma, or a severe asthma attack. Children may experience a reduced growth rate due to excessive effects of methylPREDNISolone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSE: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of methylprednisolone. Various CYP450 3A4 inhibitors including clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, mibefradil, nefazodone, and troleandomycin have been shown to increase methylprednisolone systemic exposure (AUC) by approximately 100% to 300%, with increased adrenal suppression as evidenced by reduced plasma cortisol levels.

MANAGEMENT: The possibility of increased corticosteroid effects should be considered when methylprednisolone is used with potent CYP450 3A4 inhibitors. Coadministration is not recommended unless the potential benefit to the patient outweighs the risk. If concomitant use is necessary, a 50% reduction in methylprednisolone dosage has been recommended by some investigators. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if methylprednisolone is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression. Signs and symptoms of adrenal insufficiency include anorexia, hypoglycemia, nausea, vomiting, weight loss, muscle wasting, fatigue, weakness, dizziness, postural hypotension, depression, and adrenal crisis manifested as inability to respond to stress (e.g., illness, infection, surgery, trauma).

A-methapred

Generic Name: methylprednisolone

Brand name: A-methapred, Depo-Medrol, Solu-Medrol, Medrol, Medrol Dosepak, MethylPREDNISolone Dose Pack

Synonyms: A-Methapred (injection), A-Methapred Injection

What is A-methapred?

Kaletra

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: n.a.

What is Kaletra?